Investor Presentaiton

ORFORGLIPRON: PHASE 2 TRIAL IN OBESITY DEMONSTRATED UP TO 14.7% MEAN BODY WEIGHT REDUCTION AT 36 WEEKS Percentage weight change from baseline 0- EFFICACY RESULTS Percentage Change in Body Weight by Week (efficacy estimand) Overall mean body weight at baseline -5- -10- -15- HOH HH Η HH HH HH = 109kg -2.3% -9.4% -12.5% -13.5% -14.7% KEY MESSAGES In the Phase 2 study of adults with obesity or overweight, 75% of participants achieved body weight reduction of 10% or more Safety profile was similar to other GLP-1 receptor agonists Lilly The ATTAIN Phase 3 program for orforglipron in chronic weight management began 1H of 2023 -20 24 8 12 16 20 26 32 36 Weeks Placebo (N=48) OFG 12 mg (N=44) OFG 24 mg (N=51) - OFG 36 mg (N=56) OFG 45 mg (N=57) Not for promotional use 2023 Q2 EARNINGS 14

View entire presentation